financetom
Business
financetom
/
Business
/
COVID-19: Supreme Court asks Centre to reply to PIL seeking minimum wages
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
COVID-19: Supreme Court asks Centre to reply to PIL seeking minimum wages
Apr 3, 2020 5:24 AM

The Supreme Court on Friday issued notice to the central government and sought its reply to a public interest litigation (PIL) seeking payment of minimum wages to migrant labourers affected by lockdown.

The apex court was hearing a PIL filed by social activists Harsh Mander and Anjali Bhardwaj. It was argued before the SC by advocate Prashant Bhushan.

The PIL argues that it is the duty of the Central and State Govt's ensure payment of minimum wages to migrant workers. The PIL contended that the lockdown and the manner of implementation have to lead to discrimination between different citizens. The petition also urged that the government's inaction during this humanitarian crisis has violative the fundamental right to life, of migrant workers.

Other than payment of minimum wages, the petition also seeks activation of NAtional and State Advisory Committees of Experts to prepare national and state disaster management plans.

The Solicitor General (SG) Tushar Mehta, representing the Central Govt, opposed the petition seeking relief. Referring to Prashant Bhushan, he argued that PIL shops must be closed down. The SG taunted that genuine public-spirited persons were helping on the ground. The SG argued that filing PILs while sitting in air-conditioned rooms does not help.

Nonetheless, the SG has submitted that the Centre would file a detailed response on migrant workers as per SC directions. The matter is due to be heard next on April 7.

First Published:Apr 3, 2020 2:24 PM IST

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Delaware judge says she will not block Metsera from ending Pfizer deal 
Delaware judge says she will not block Metsera from ending Pfizer deal 
Nov 5, 2025
WILMINGTON, Delaware, Nov 5 (Reuters) - A Delaware judge said on Wednesday she would reject a request by Pfizer ( PFE ) to temporarily block Metsera ( MTSR ) from terminating its takeover deal with Pfizer ( PFE ), allowing Metsera ( MTSR ) to proceed instead with a higher $10 billion deal from Novo Nordisk. ...
Jazz Pharmaceuticals Q3 revenue beats estimates
Jazz Pharmaceuticals Q3 revenue beats estimates
Nov 5, 2025
Overview * Jazz Pharmaceuticals ( JAZZ ) Q3 revenue grows 7% yr/yr, beating analyst expectations * Adjusted EPS for Q3 beats consensus, reflecting robust operational performance * Company narrows 2025 revenue guidance to $4.175 - $4.275 bln Outlook * Company narrows 2025 revenue guidance to $4.175 - $4.275 bln * Jazz Pharmaceuticals ( JAZZ ) expects top-line data from zanidatamab...
World Kinect Corporation Completes Acquisition of Universal Weather and Aviation's Trip Support Services Business
World Kinect Corporation Completes Acquisition of Universal Weather and Aviation's Trip Support Services Business
Nov 5, 2025
MIAMI--(BUSINESS WIRE)-- World Kinect Corporation ( WKC ) today announced that it has completed its previously announced acquisition of the Trip Support Services (TSS) division of Universal Weather and Aviation. Universal Weather, headquartered in Houston, Texas, has been a pioneer in trip support services with deep expertise in international travel regulations, logistics, and supply chain management. Its trip support business...
Cardiac muscle therapeutics firm Cytokinetics Q3 net loss widens
Cardiac muscle therapeutics firm Cytokinetics Q3 net loss widens
Nov 5, 2025
Overview * Cytokinetics ( CYTK ) Q3 net loss widens to $306.2 mln, driven by debt conversion expense * Company reports Q3 revenue of $1.9 mln, up from $0.5 mln last year * Cytokinetics ( CYTK ) prepares for potential U.S. launch of aficamten pending FDA approval Outlook * Company expects EMA decision on aficamten MAA in 1H 2026 *...
Copyright 2023-2026 - www.financetom.com All Rights Reserved